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I T is well established that perioperative fluid management influences postoperative complication rates in major gas-
trointestinal surgery.1–4 However, the optimal intraoperative 
fluid regimen is still controversial in terms of how much 
fluid to infuse, choice of fluids (crystalloids or colloids), use 
of vasopressors, or a goal-directed hemodynamic therapy 
(GDT).1–4
Restrictive intraoperative hydration has shown ambigu-
ous results, some showing a reduced postoperative morbid-
ity,1,3 whereas others found no benefit in terms of reduction 
of complications.5–7 However, the impact of intraoperative 
restrictive deferred crystalloid hydration combined with the 
administration of preemptive continuous norepinephrine 
infusion on the postoperative complication rate has not yet 
been investigated in patients undergoing major gastrointes-
tinal surgery. Norepinephrine, which has a strong α- and 
only a mild β-adrenergic effect, may counteract anesthe-
sia-induced vasodilation and consequent hypotension and 
ensure sufficient organ perfusion.8 This could be a valuable 
alternative to IV fluid boluses, as liberal hydration is known 
to cause interstitial edema and increased postoperative 
complications.1,3
To test this hypothesis in a major surgery model we chose 
open radical cystectomy combined with pelvic lymph node 
dissection and urinary diversion, because it is an extensive 
and time-consuming but standardized surgical interven-
tion in a high case-load tertiary center. In addition, despite 
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acts this effect and thus allows for decreased intraoperative hydration. The authors investigated whether this approach could 
result in reduced postoperative complication rate.
Methods: In this single-center, double-blind, randomized, superiority trial, 166 patients undergoing radical cystectomy and 
urinary diversion were equally allocated to receive 1 ml·kg−1·h−1 of balanced Ringer’s solution until the end of cystectomy and 
then 3 ml·kg−1·h−1 until the end of surgery combined with preemptive norepinephrine infusion at an initial rate of 2 µg·kg−1·h−1 
(low-volume group; n = 83) or 6 ml·kg−1·h−1 of balanced Ringer’s solution throughout surgery (control group; n = 83). Primary 
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Results: In-hospital complications occurred in 43 of 83 patients (52%) in the low-volume group and in 61 of 83 (73%) in the 
control group (relative risk, 0.70; 95% CI, 0.55–0.88; P = 0.006). The rates of gastrointestinal and cardiac complications were 
lower in the low-volume group than in the control group (5 [6%] vs. 31 [37%]; relative risk, 0.16; 95% CI, 0.07–0.39; P < 
0.0001 and 17 [20%] vs. 39 [48%], relative risk, 0.43; 95% CI, 0.26–0.60; P = 0.0003, respectively). The median hospitaliza-
tion time was 15 days [range, 11, 27d] in the low-volume group and 17 days [11, 95d] in the control group (P = 0.02). The 
90-day mortality was 0% in the low-volume group and 4.8% in the control group (P = 0.12).
Conclusion: A restrictive-deferred hydration combined with preemptive norepinephrine infusion during radical cystectomy 
and urinary diversion significantly reduced the postoperative complication rate and hospitalization time. (Anesthesiology 
2014; 120:365-77)
What We Already Know about This Topic
•	 Norepinephrine	counteracts	the	vasodilating	effects	of	anes-
thesia,	 thus	 allowing	 blood	 pressure	 to	 be	maintained	 with	
less	fluid	administration
•	 In	a	randomized	trial,	 the	 investigators	compared	major	out-
comes	 in	 patients	 given	 conventional	 amounts	 of	 fluid	 with	
fluid	sparing	induced	by	norepinephrine	administration
What This Article Tells Us That Is New
•	 The	 incidence	 of	 major	 complications	 was	 significantly	 re-
duced,	with	a	relative	risk	of	0.7	(95%	CI,	0.55–0.88)
•	 The	duration	of	hospitalization	was	also	significantly	reduced	
from	a	median	of	17	to	15	days
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Intraoperative Hydration and Postoperative Complications
improvements in surgical technique and perioperative care, 
radical cystectomy is associated with early postoperative 
complication rates of 26–64%9–13 and a 90-day mortality 
rate of 2–7%.12–14
The goal of this study was to compare the impact of 
intraoperative restrictive deferred hydration combined with 
preemptive infusion of norepinephrine versus that of a more 
liberal crystalloid hydration (including fluid preloading dur-
ing induction and “generous” intraoperative hydration) on 
in-hospital complication rates, hospitalization time, 90-day 
postoperative complications, and mortality in patients 
undergoing pelvic lymph node dissection, radical cystec-
tomy, and urinary diversion.
Material and Methods
Trial Design and Participants
This prospective, single-center, double-blind (patient, data 
assessor, and surgeon), parallel-group, randomized, con-
trolled superiority trial was approved by the local ethics com-
mittee (Kantonale Ethikkommission Berne, KEKBE154/08) 
and registered at ClinicalTrials.gov (NCT01276665). 
After providing written informed consent, 190 consecu-
tive patients were assessed for eligibility between November 
2009 and September 2012 (fig. 1).
Patients with American Society of Anesthesiologists phys-
ical status II or III undergoing pelvic lymph node dissection 
and open radical cystectomy with either an ileal conduit or 
an ileal orthotopic bladder substitution for urinary diver-
sion were included. Exclusion criteria were known coagu-
lopathies, significant hepatic dysfunction (prothrombin 
ratio <50%), significant renal dysfunction (estimated glo-
merular filtration rate <60 ml/min), congestive heart failure 
(New York Heart Association scores ≥3), and contraindica-
tions for epidural analgesia.
Randomization and Masking
The randomization sequence was created by computer-
generated permuted block randomization with 1:1 alloca-
tion. The allocation sequence was concealed in opaque 
sealed envelopes that were sequentially numbered. The 
randomization sequence was kept concealed until after 
written consent had been obtained. Patients were allo-
cated to the groups by assigning them the sequentially 
numbered envelope with the lowest number. Stratifica-
tion was done for the type of urinary diversion (ileal con-
duit vs. ileal orthotopic bladder substitution). Patients, 
urologists, and data assessors were blinded to group 
assignment. In order to blind the surgeons, crystalloid 
bags and perfusion pumps were placed behind an opaque 
panel during surgery and were not visible to the urolo-
gists. Data were recorded prospectively in a standardized 
case report form. Assessors of the postoperative data had 
no access to the anesthesiologic patients’ data as these 
were kept sealed.
Preoperative Care, Surgery, Anesthesia, and Monitoring
No antegrade bowel preparation was used. Patients fasted till 
midnight and could drink clear drinks till 2 h before surgery. 
All patients were premedicated with midazolam (7.5 mg) 
or lorazepam (1 mg) 30 min before induction of anesthe-
sia. Surgery was standardized and performed as previously 
described with the patient in a 30° head-down position in 
the presence of one senior urologist (Drs. Burkhard, Thal-
mann, and Studer).15–17
Standard monitoring included continuous electrocar-
diographic data, heart rate, nasopharyngeal core tempera-
ture, pulse oxymetry, invasive mean arterial pressure (MAP) 
with a radial artery catheter and central venous pressure 
with a venous catheter inserted in the right jugular vein. 
For study purposes, an esophageal Doppler probe (Deltex 
Medical Ltd., Chichester, United Kingdom) was inserted 
immediately after induction of anesthesia and placed to 
obtain the best possible Doppler velocity signal from the 
descending aorta. Stroke volume, cardiac output, and cor-
rected flow time were recorded. An epidural catheter was 
placed at the T9/T10 level: an 18-gauge epidural needle 
was inserted by a paramedian approach and the epidural 
space was identified with the loss-of-resistance technique. 
After a test dose of 1.5 ml lidocaine 2% with 0.005 mg/
ml epinephrine to rule out subarachnoidal or intravas-
cular placement, a 0.25% bupivacaine infusion at a rate 
of 8 ml/h was administrated until the end of the pelvic 
lymph node dissection and then stopped until closure of 
the abdominal wall. Anesthesia was induced with propofol 
(2 mg/kg), fentanyl (2 µg/kg), rocuronium (0.6 mg/kg) and 
maintained with isoflurane at an age-corrected minimum 
alveolar concentration of 0.6. Ventilation with an inspired 
oxygen fraction of 60% was mechanically controlled to 
maintain ParterialCO2 between 35 and 40 mmHg, with a 
positive end-expiratory pressure of 5 mmHg and tidal vol-
ume of 8 ml/kg. Normothermia was maintained with a 
convective air warming system (Bair Hugger; 3M-Switzer-
land, Rüschlikon, Switzerland) and a Hotline® fluid warmer 
(Smith Medical International Ltd., Ashford, Kent, United 
Kingdom).
Intraoperative Fluid Therapy
Restrictive Deferred Fluid Group with Preemptive 
Norepinephrine Administration (“Low-volume Group”). After 
induction of anesthesia, a preemptive norepinephrine infu-
sion was started at a rate of 2 µg·kg−1·h−1 until the end of 
surgery and a balanced Ringer’s solution (Ringerfundin®; B. 
Braun Medical AG, Sempach, Switzerland) was infused at 
a rate of 1 ml·kg−1·h−1 until the bladder was removed, fol-
lowed by 3 ml·kg−1·h−1 of balanced Ringer’s solution until 
the end of surgery (deferred hydration). If hypotension was 
observed (MAP <60 mmHg), norepinephrine infusion rate 
was titrated to maximum 8 µg·kg−1·h−1 after an initial bolus 
of 10 µg. If hypotension persisted, a bolus of 250 ml of bal-
anced Ringer’s solution was given.
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Control Group.  A preload bolus of 6 ml/kg of balanced Ring-
er’s solution was administrated during induction of anesthe-
sia. After that, balanced Ringer’s solution was infused at a 
constant rate of 6 ml·kg−1·h−1 until the end of surgery. If 
hypotension was observed (MAP <60 mmHg) a bolus of 
250 ml balanced Ringer’s solution was given and in case 
of persistent hypotension this procedure was repeated to a 
maximum of 10 boluses.
In both groups, blood loss of greater than 500 ml was 
substituted with an equal amount of balanced Ringer’s solu-
tion. Packed erythrocytes units were transfused if hemoglo-
bin values were less than 8 g/dl (<10 g/dl in patients with 
coronary artery disease). Fresh frozen plasma transfusion 
was administrated in the presence of continuous excessive 
microvascular bleeding (relative indication based on the 
senior surgeons’ observations) or if prothrombin time was 
greater than 1.5 times normal.18 Colloid solution (Volu-
ven balanced®; Fresenius Kabi AG, Stans, Switzerland) was 
only infused as a rescue medication if a MAP less than 60 
mmHg persisted after the abovementioned correction with 
balanced Ringer’s solution, and in case of severe metabolic 
acidosis (base excess <−5, pH <7.25) attributable to severe 
hypovolemia.
Intra- and Postoperative Biomarkers
Serum lactate and central venous oxygen saturation 
(ScvO2) were assessed after induction of anesthesia, after cys-
tectomy, after urinary diversion, at the end of surgery, and 
on postoperative day (POD) 1. Hemoglobin, hematocrit, 
C-reactive protein, procalcitonin, albumin, and creatinine 
levels were assessed preoperatively, on PODs 1, 2, and 5. 
The cardiac biomarkers high-sensitive troponin T, brain 
natriuretic peptide (BNP), serum and urine osmolality, were 
assessed preoperatively, on PODs 1 and 2. At hospital dis-
charge, hemoglobin, hematocrit, creatinine, and BNP serum 
levels were assessed.
Postoperative Patient Management
The epidural analgesia was reactivated during closure of 
the abdominal wall with a mixture composed of bupiva-
caine 0.1%, fentanyl 2 µg/ml, and epinephrine 2 µg/ml 
using a CADD-Legacy ambulatory infusion pump (model 
Lost to follow-up (n=0) 
Discontinued intervention (n=1) 
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Allocated to intervention (n=83) 
♦ Received allocated intervention (n=83)
♦ Did not receive allocated intervention (n=0)
Allocated to intervention (n=84) 
♦ Received allocated intervention (n=84)
♦ Did not receive allocated intervention (n=0)
Randomized (n=167) 
Excluded (n=23) 
♦ Did not meet inclusion criteria (n=12) 
♦ Declined to participate (n=11) 
Assessed for eligibility (n=190) 
Analysed (n=83) 
♦ Excluded from analysis (n=0)
Analysed (n=83) 
♦ Excluded from analysis (n=0)
Fig. 1. Consolidated Standards of Reporting Trials flow diagram.
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6300; Deltec Inc., St. Paul, MN). The initial infusion rate 
was 8 ml/h, with a maximum infusion rate till 15 ml/h, and 
with additional bolus volumes of 5 ml (lockout time: 1 h). 
After surgery patients were admitted to the intermediate 
care unit. IV paracetamol and metamizol (both 1 g every 
6 h) were given postoperatively. The epidural catheter was 
removed on POD 5.
Postoperative hydration was identical in both groups 
and consisted primarily of 1,000 ml of balanced Ringer’s 
solution and 500 ml of glucose 5% per 24 h until resump-
tion of normal food intake.19 If the MAP were less than 60 
mmHg, first, a bolus of 500 ml of balanced Ringer’s solu-
tion was administrated, second, by persistent MAP less 
than 60 mmHg, norepinephrine was infused up to a rate 
of 200 µg/h. Packed erythrocytes units were transfused 
according to the American Society of Anesthesiologists 
guidelines,20 and fresh frozen plasma transfusion was given 
if the prothrombin time was greater than 1.5 times the 
normal value. The amounts of packed erythrocytes units, 
fresh frozen plasma units, and fluids given postoperatively 
were recorded.
Postoperative patients were allowed to drink clear fluids 
immediately. A peroral liquid diet was started on POD 1 as 
well as active mobilization. To enhance recovery of bowel 
function, the use of chewing gum was encouraged21 and sub-
cutaneous application of neostigmine 0.05 mg was started 
on POD 2. Flatus and stool passage were recorded. Body 
weight was measured daily. Perioperative antibiotic ther-
apy consisted of obramycin and metronidazole for 2 days 
and amoxicillin/clavulanic acid until removal of all stents 
and catheters. Low–molecular-weight heparin was started 
on the evening before surgery and maintained throughout 
hospitalization.
Outcome Measures
The primary endpoint was the in-hospital complication 
rate assessed according to a modified postoperative mor-
bidity survey and Clavien–Dindo classification for radi-
cal cystectomy3,22 (appendix). Secondary endpoints were 
 hospitalization time, the 90-day postoperative compli-
cation rate according to the Clavien–Dindo classifica-
tion,10,23 and 90-day mortality. Start of the hospitalization 
time was defined as the moment the patient was admit-
ted into the hospital (in all cases the day before surgery). 
Discharge criteria were: removal of all drains and cath-
eters, and the ability to handle the urostoma bag or empty 
the ileal orthotopic neobladder spontaneously and free of 
residual urine.
All outcome measures were registered by assessors blinded 
to the intraoperative fluid regimen.
Statistics
On the basis of the assumption that the application of intra-
operative restrictive deferred fluid regimen with preemptive 
norepinephrine infusion would reduce the complication rate 
from 3811–13 to 20%, a sample size of 83 patients per group 
was calculated for each group with a type I error of 0.05 and 
a power of 80%. Data were analyzed on a modified inten-
tion-to-treat basis (one patient was excluded after random-
ization because the initially planned surgery was cancelled). 
Data are expressed with medians with ranges for continu-
ous variables or frequencies for categorical ones. Categorical 
data were compared with the Fisher exact or the chi-square 
test and continuous data with the Mann–Whitney U test 
as appropriate. Relative risks (RRs) and 95% CIs were also 
calculated. The primary outcome was analyzed using Fisher 
exact test with RR and 95% CI. The significance level was 
set at 0.05.
Multiple logistic regression analyses using a full model 
were applied to identify independent risk factors for post-
operative complications and reported as adjusted odds ratios 
(ORs) with 95% CIs. Confounders considered were groups 
(low-volume vs. control group), type of urinary diversion 
(ileal conduit vs. ileal orthotopic blabber substitution), age 
(categorized into: <65 yr, 65–74 yr, 75–84 yr, ≥85 yr), 
neoadjuvant chemotherapy, preoperative anemia, Ameri-
can Society of Anesthesiologists physical status score (II vs. 
III), Charlson Comorbidity Index age adjusted, Glasgow 
Prognostic Score, body mass index, and preoperative serum 
BNP values. Interaction terms were not included because of 
insufficiently large sample size. Confounders were consid-
ered as significant if their P values were less than 0.10. The 
fit and predictive capability of the model was assessed using 
the Hosmer–Lemeshow goodness-of-fit test and receiver 
operating characteristic area under the curve. The statisti-
cal softwares used were SPSS 19.0 (SPSS Inc., Chicago, IL) 
and Statistical Analysis System software (version 9.3; SAS 
Institute, Cary, NC).
Results
Of 190 consecutive patients, 167 fulfilled the eligibility 
criteria and were randomized. One of these patients was 
excluded because the intervention was aborted, leaving 166 
patients included in the final analysis (fig. 1). Complete 
follow-up data were available for all 166 participants. Pre-
operative and patient characteristics were similar for the two 
groups (table 1).
The total median volume of balanced Ringer’s solution 
infused intraoperatively was 1,700 ml [range, 700, 4,000 
ml] in the low-volume group versus 4,300 ml [2,800, 
6,200 ml] in the control group; P < 0.0001 (table 2). 
The median dose of norepinephrine administered intra-
operatively to the low-volume group was 3.6 µg·kg−1·h−1 
[2.0–8.0 µg·kg−1·h−1]. Neither group was given colloid 
solution. Significantly lower median cardiac output val-
ues were observed in the low-volume group than in the 
control group during the periods of cystectomy (3.7 l/
min [2.2–8.7 l/min] vs. 4.8 l/min [1.7–11.9 l/min]; 
P = 0.002) and urinary diversion (4.2 l/min [2.4–7.3 l/
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min] vs. 5.0 l/min [2.3–11.1 l/min]; P = 0.003) but not 
at the end of surgery (table 2). In both groups, cardiac 
output values at the end of surgery did not differ sig-
nificantly from values at the beginning of surgery. On 
POD 1, a significantly greater increase in body weight 
was observed in the control group (2.0 kg [−2, +7 kg]) 
than in the low-volume group (0.0 kg [−3, +4 kg]; 
P < 0.0001; table 3).
In-hospital Complications
In-hospital complications occurred in 43 of 83 patients 
(52%) in the low-volume group versus 61 of 83 patients 
(73%) in the control group (RR, 0.70; 95% CI, 0.55–0.88; 
P = 0.006). The absolute reduction in the number of patients 
experiencing complications was 22% (95% CI, 7–36%). 
The total number of complications was 77 in the low-vol-
ume group versus 161 in the control group (P < 0.0001; 
table 4). According to the Clavien–Dindo classification, 
the majority of complications were minor (Clavien–Dindo 
classification grade 1 or 2) in both groups: low-volume 
group (33 of 83 patients; 40%) and control group (42 of 83 
patients; 51%; fig. 2).
Gastrointestinal complications occurred in 5 of 83 (6%) 
of the low-volume group versus 31 of 83 (37%) of the con-
trol group (RR, 0.16; 95% CI, 0.07–0.39; P < 0.0001). 
The most common complications observed were ileus and 
constipation, which occurred in 0 of 83 (0%) and 2 of 83 
(2%) patients of the low-volume group versus 8 of 83 (10%) 
and 18 of 83 (22%) of the control group (P = 0.007 and 
P = 0.0006, respectively; table 4).
Cardiac events occurred in 17 of 83 patients (20%) 
of the low-volume group versus 40 of 83 patients (48%) 
in the control group (RR, 0.43; 95% CI, 0.26–0.69; P = 
0.0003). The majority of cardiac events were minor com-
plications consisting of a transient increase of BNP dur-
ing the two first PODs: 11 of 83 (13%) patients in the 
low-volume group versus 28 of 83 (34%) patients in the 
control group (RR, 0.39; 95% CI, 0.21–0.74; P = 0.003). 
The incidences of the major complications such as acute 
myocardial infarction and congestive heart failure did not 
differ between the two groups, nor did the rates of renal, 
infectious, pulmonary, and thromboembolic complica-
tions (table 4).
Multiple logistic regression analyses identified group allo-
cation (low-volume vs. control group: OR, 0.44 [95% CI, 
0.21–0.92]; P = 0.029), body mass index (per increasing 
value: OR, 1.13 [95% CI, 1.01–1.25]; P = 0.029), BNP 
(per increasing value BNP: OR, 1.01 [95% CI, 1.00–1.03]; 
P = 0.045), preoperative anemia (no vs. yes: OR, 0.426 [95% 
CI, 0.18–1.02]; P = 0.056), and Glasgow Prognostic Score 
(per increasing value: 1.61 [95% CI, 0.93–2.88]; P = 0.089) 
as independent predictors of complications (Hosmer–Lem-
eshow test: P = 0.685 and receiver operating characteristic 
area under the curve: 0.78; table 5).
Length of Hospital Stay, 90-day Postoperative 
Complication Rate, and Mortality
The median length of hospital stay was 15 days [11, 27d] in 
the low-volume group and 17 days [10, 95d] in the control 
group (P = 0.01).
The total number of patients experiencing complica-
tions within the 90th POD was lower in the low-volume 
group (44 of 83; [53%]) than in the control group (64 of 83 
[77%]; P = 0.0019). The majority of complications in both 
groups were classified as minor (grade 1 or 2; table 6).
The 30-day and 90-day overall mortality rates were 0 
and 2.4%, respectively. No patient in the low-volume group 
died, but four patients (4.8%) in the control group did 
(P = 0.12). Two patients died because of rapid disease prog-
ress, one died of septic shock, and one of pneumonia. Three 
of these patients were older than 75 yr.
Discussion
Intraoperative restrictive deferred hydration combined with 
preemptive norepinephrine infusion was associated with 
significantly reduced in-hospital and 90-day postoperative 
complication rates and a shortened hospitaliza tion time.
Consistent with other reports10,24 constipation and ileus 
were the most frequently observed gastrointestinal com-
plications in our patients receiving more liberal crystalloid 
hydration, despite the use of the modified Clavien–Dindo 
classification for radical cystectomy,10 which has rarely been 
applied in other studies. In the low-volume group, gastroin-
testinal complications were significantly lower with a more 
rapid recovery of bowel function, which is of relevance 
because gastrointestinal dysfunction can lead to prolonged 
hospitalization.22,25 The postoperative body weight increase 
and the hypoalbuminemia observed in the control group 
reflect overhydration, which is known to delay recovery of 
bowel motility because of excess fluid in the intestinal wall.19 
Excess of fluid leads to shedding of the glycocalyx followed 
by extravasation and edema.26
The number of cardiac events was high in both groups, 
but significantly lower in the low-volume group; however, 
it has to be stated that in both groups most cardiac events 
were a transient increase of serum BNP. Severe cardiac 
complications like arrhythmia, congestive heart failure, 
and acute myocardial infarction did not differ between 
the groups. Serum BNP release is directly proportional 
to ventricular volume expansion, and thus the transient 
BNP increases observed in the control group may reflect 
a perioperative volume overload and correlates with Berri 
et al.’s27 observations, where a postoperative serum BNP 
increase was associated with a positive fluid balance in 
patients undergoing pancreatectomy. In addition, a post-
operative BNP increase has been associated with prolonged 
hospitalization time in patients undergoing major ortho-
pedic surgery.28 The number of arrhythmias and myocar-
dial infractions, complications that could be attributed to 
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norepinephrine, were not different between the groups. 
Our results show that the use of norepinephrine combined 
with a low-volume fluid regimen as administered in our 
study was safe and not detrimental to cardiac function, as 
has often been postulated.
A frequently used argument against restrictive intraop-
erative hydration is the fear of increased infectious com-
plications attributable to hypovolemia and the ensuing 
tissue hypoperfusion.2 In our low-volume group, the rate 
of infectious complications was not increased. On POD 1, 
the patients’ body weight and urine osmolality, factors that 
mirror hydration status, were comparable with the preop-
erative values, indicating a zero fluid balance rather than 
hypovolemia. An ScvO2 value less than 70% is considered an 
early marker for tissue hypoperfusion and is associated with 
increased postoperative complications.29,30 ScvO2 remained 
Table 1. Preoperative Patient Characteristics
Characteristic
Low-volume Group
(n = 83)
Control Group
(n = 83)
Age (yr) 68 [38–88] 69 [42–88]
  <65 26 (31%) 31 (37%)
  65–74 36 (43%) 25 (30%)
  75–84 17 (21%) 22 (27%)
  ≥85 4 (5%) 5 (6%)
Body weight (kg) 74 [40–160] 77 [41–112]
BMI (kg/m2) 24 [18–42] 24 [20–39]
Sex (female/male) 27/56 (33%/67%) 25/58 (30%/70%)
ASA physical status score
  2 52 (63%) 46 (55%)
  3 31 (37%) 37 (45%)
CCI age adjusted
  0–2 14 (17%) 23 (28%)
  3–5 61 (73%) 49 (59%)
  >5 8 (10%) 11(13%)
Glasgow Prognostic Score
  0 36 (44%) 29 (35%)
  1 28 (34%) 38 (46%)
  2 18 (22%) 16 (19%)
NYHA functional classification
  0 62 (75%) 61 (73%)
  1 6 (7%) 4 (5%)
  2 15 (18%) 18 (22%)
Hypertension 41 (44%) 53 (56%)
Diabetes mellitus 10 (12%) 6 (7%)
COPD 19 (23%) 17 (21%)
Aspirin 21 (25%) 15 (18%)
Antihypertensives 36 (43%) 48 (58%)
Statin 16 (19%) 16 (19%)
β-Blocker 13 (16%) 22 (27%)
Neoadjuvant chemotherapy 11 (13%) 13 (16%)
Preoperative anemia 27 (33%) 39 (47%)
Hemoglobin (g/dl) 12.9 [8.4–15.9] 12.6 [7.3–16.7]
Hematocrit 0.38 [0.25–0.48] 0.37 [0.25–0.50]
Thrombocytes (g/l) 250 [122–211] 252 [111–770]
Glucose (mM) 6.26 [4.1–13.5] 6.30 [4.2–13.0]
C-reactive protein (mg/l) 3 [3–197] 3 [3–92]
Procalcitonin (ng/ml) 0.1 [0.0–0.5] 0.1 [0.0–0.36]
Serum creatinine (µM) 81 [34–120] 80 [34–150]
eGFR (MDRD)/1.73 m2 (ml/min) 76 [60–90] 76 [60–90]
Albumin (g/l) 35 [19–48] 34 [18–46]
Osmolality (mosmol/kg) 289 [278–300] 289 [267–298]
Brain natriuretic peptide (pg/ml) 25 [5–350] 29 [5–341]
High-sensitive troponin T (µg/l) 0.01 [0.01–0.016] 0.01 [0.01–0.015]
Data are presented as median [range] or absolute value (%). There were no significant differences between the groups. Anemia definition according to the 
World Health Organization: hemoglobin <13 g/dl for men and <12 g/dl for women.
ASA = American Society of Anesthesiologists; BMI = body mass index; CCI = Charlson Comorbidity Index; COPD = chronic obstructive pulmonary disease; 
eGFR = estimated glomerular filtration rate; MDRD = modification of diet in renal disease; NYHA = New York Heart Association.
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greater than 70% in our low-volume group, indicating an 
adequate balance between oxygen delivery and consump-
tion. Serum lactate is another indicator of tissue oxygen-
ation, and a serum lactate greater than 2 mM indicates 
acidosis. The low number of patients in both groups with 
postoperative serum lactate levels greater than 2 mM and the 
median serum lactate levels of less than 1.5 mM observed 
perioperatively are comparable with those levels in studies 
Table 2. Intraoperative Parameters
Low-volume Group  
(n = 83)
Control Group
(n = 83) P Value
Type of surgery 0.34
  Ileum conduit 32 (39%) 39 (47%)
  Ileal orthotopic bladder substitution 51 (61%) 44 (53%)
Total duration of surgery (min) 390 [240–570] 390 [210–585] 0.92
Blood loss (ml) 800 [300–1,800] 1,200 [400–3,000] <0.0001
Volume of intraoperative fluid given
  Total volume of crystalloid (ml) 1,700 [700–4,000] 4,300 [2,800–6,200] <0.0001
  Total volume of crystalloid perfused (ml·kg−1·h−1) 3.5 [1.3–6.0] 8.8 [5.1–16.7] <0.0001
  Fresh frozen plasma perfused (ml) 0 [0–600] 0 [0–1,200] 0.001
  Allogeneic blood transfused (ml) 0 [0–600] 0 [0–2,100] <0.0001
  Total volume of fluid perfused (ml·kg−1·h−1) 3.6 [1.3–5.2] 9.3 [5.2–16.7] <0.0001
Mean arterial pressure (mmHg)
  During pelvic lymph nodes dissection 70 [55–100] 68 [55–90] 0.14
  During cystectomy 70 [57–93] 70 [55–100] 0.38
  During urinary diversion 60 [60–102] 70 [55–92] 0.17
Heart frequency (beats/min)
  During pelvic lymph node dissection 66 [45–94] 63 [45–90] 0.25
  During cystectomy 69 [43–102] 63 [40–90] 0.09
  During urinary diversion 76 [41–107] 74 [40–98] 0.06
Central venous pressure (mmHg)
  During pelvic lymph node dissection 12 [5–21] 15 [5–23] <0.0001
  During cystectomy 12 [2–23] 16 [3–25] <0.0001
  During urinary diversion 10 [3–22] 14 [3–29] <0.0001
Cardiac output (l/min)
  Start of surgery 4.4 [2.3–8.8] 4.9 [2.7–10.7] 0.22
  During pelvic lymph node dissection 3.7 [2.3–7.7] 4.4 [1.8–11.8] 0.11
  During cystectomy 3.7 [2.2–8.7] 4.8 [1.7–11.9] 0.0019
  During urinary diversion 4.2 [2.4–7.3] 5.0 [2.3–11.1] 0.0034
  End of surgery 4.2 [2.4–9.6] 5.1 [2.8–13.8] 0.10
Stroke volume (ml)
  Start of surgery 70 [36–122] 77 [35–210] 0.06
  During pelvic lymph node dissection 60 [37–144] 73 [34–205] 0.0126
  During cystectomy 57 [30–120] 77 [32–188] 0.0007
  During urinary diversion 58 [25–115] 72 [32–168] 0.0003
  End of surgery 56 [26–130] 72 [37–175] 0.0121
Corrected flow time (ms)
  Start of surgery 320 [209–420] 333 [238–424] 0.0389
  During pelvic lymph node dissection 300 [203–411] 329 [224–426] 0.0257
  During cystectomy 291 [217–388] 328 [217–413] 0.0005
  During urinary diversion 295 [182–390] 337 [213–439] <0.0001
  End of surgery 304 [211–405] 327 [306–436] 0.0067
Intraoperative ScvO2 (%)
  Start of surgery 85 [66–89] 86 [73–89] 0.50
  End cystectomy 80 [58–89] 82 [54–89] 0.40
  End surgery 82 [58–84] 83 [60–89] 0.87
Intraoperative serum lactate (mM)
  Start of surgery 1 [0.6–0.8] 0.9 [0.6–2.4] 0.15
  End cystectomy 1.2 [0.6–2.0] 1.0 [0.5–3.1] 0.0008
  End surgery 1.3 [0.7–4.2] 1.2 [0.6–2.6] 0.06
Data are presented as median [range] or absolute value (%).
ScvO2 = central venous oxygen saturation.
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Table 3. Postoperative Fluid Administration, Body Weight Differences, Renal, Metabolic, Inflammatory, and Cardiac Biomarkers
Characteristic
Low-volume Group
(n = 83)
Control Group
(n = 83) P Value
Postoperative day 1
  Total fluid volume perfused (ml) 2,100 [800–4,000] 2,050 [1,000–4,100] 0.90
  Weight difference vs. preop (kg/BW) +0.0 [−3 to +4] +2 [−2 to +7] <0.0001
  ScvO2 (%) 80 [43–98] 80 [68–98] 0.14
  Serum lactate (mM) 1.1 [0.6–2.3] 1.0 [0.5–5.1] 0.81
  Number of patients with lactate level >2 mM 3 (4%) 2 (2%)
  Hemoglobin (g/dl) 8.5 [5.4–12.6] 8.2 [5.3–11.7] 0.47
  Hematocrit 0.25 [0.16–0.37] 0.25 [0.16–0.34] 0.52
  Serum creatinine (µM) 94 [53–269] 84 [43–200] 0.02
  eGFR (MDRD)/1.73 m2 (ml/min) 67 [19–90] 74 [26–90] 0.02
  Serum osmolality (mosmol/kg) 288 [278–300] 289 [267–297] 0.15
  Urine osmolality (mosmol/kg) 510 [216–979] 553 [244–843] 0.64
  Albumin (g/l) 32 [23–48] 31 [20–54] 0.0027
  Procalcitonin (ng/ml) 1.1 [0.1–25.1] 1.1 [0.1–9.2] 0.95
  C-reactive protein (mg/l) 85 [42–171] 81 [3–242] 0.64
  Brain natriuretic peptide (pg/ml) 50 [5–419] 72 [5–962] 0.0187
  High-sensitive troponin T (µg/l) 0.01 [0.001–0.22] 0.01 [0.001–0.065] 0.46
Postoperative day 2
  Total fluid volume perfused (ml) 1,500 [400–3,200] 1,750 [1,000–3,900 0.07
  Weight difference vs. POD 1 (kg/BW) +0.4 [−4 to +3] −0.5 [−5 to +3] <0.0001
  Hemoglobin(g/dl) 8.4 [5.7–11.3] 8.1 [5.8–10.5] 0.33
  Hematocrit 0.25 [0.17–0.34] 0.24 [0.17–0.31] 0.50
  Serum creatinine (µM) 78 [45–303] 75 [39–212] 0.48
  eGFR (MDRD)/1.73 m2 (ml/min) 76 [27–90] 82 [26–90] 0.39
  Serum osmolality (mosmol/kg) 284 [270–299] 283 [269–304] 0.13
  Urine osmolality (mosmol/kg) 472 [176–808] 486 [134–834] 0.67
  Albumin (g/l) 31 [25–38] 32 [20–39] 0.97
  C-reactive protein (mg/l) 182 [57–331] 188 [9–398] 0.47
  Procalcitonin (pg/l) 0.9 [0.2–20.4] 0.9 [0.1–8.9] 0.31
  Brain natriuretic peptide (pg/ml) 87 [5–822] 102 [5–567] 0.16
  High-sensitive troponin T (µg/l) 0.01 [0.001–0.137] 0.01 [0.001–0.069] 0.07
Postoperative day 3
  Total fluid volume perfused (ml) 1,500 [500–2,500] 1,500 [500–2,800] 0.13
  Weight difference vs. POD 2 (kg/BW) −0.2[−4 to +5] 0 [−3 to +4] 0.63
  Serum creatinine (µM) 75 [38–339] 72 [38–191] 0.77
  eGFR (MDRD)/1.73 m2 (ml/min) 79 [31–90] 85 [29–90] 0.38
  Albumin (g/l) 29 [23–38] 29 [19–39] 0.68
  C-reactive protein (mg/l) 160 [30–320] 183 [12–480] 0.15
  Procalcitonin (pg/l) 0.7 [0.1–13.1] 0.8 [0.1–13.1] 0.56
Postoperative day 4
  Total fluid volume perfused (ml) 1,000 [500–2,500] 1,000 [500–3,500] 0.17
  Weight difference vs. POD 3 (kg/BW) 0 [−4.1 to +7.9] 0 [−4.2 to +5.0] 0.52
Postoperative day 5
  Total fluid volume perfused (ml) 1,000 [500–3,500] 1,000 [500–2,100] 0.30
  Weight difference vs. POD 4 (kg/BW) 0 [−4 to +7] 0 [−5 to +6] 0.79
  Hemoglobin (g/dl) 9.3 [6.3–13.2] 9.4 [7.0–12.1] 0.60
  Hematocrit 0.28 [0.18–0.42] 0.28 [0.19–0.36] 0.79
  Serum creatinine (µM) 72 [28–234] 72 [40–233] 0.39
  eGFR (MDRD)/1.73 m2 (ml/min) 84 [32–90] 88 [24–90] 0.33
  Albumin (g/l) 27 [20–37] 27 [19–35] 0.64
  C-reactive protein (mg/l) 84 [7–480] 95 [3–510] 0.48
  Procalcitonin (pg/l) 0.4 [0.1–8.3] 0.4 [0.1–12.0] 0.80
(Continued)
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using hemodynamic optimization strategies (GDT).2,31 The 
nonsignificant difference in infectious complications fur-
ther corroborates adequate tissue perfusion and the safety 
of the restrictive deferred hydration combined with preemp-
tive norepinephrine infusion. The significantly lower 90-day 
complication rate in the low-volume group is particularly 
noteworthy in these patients who are at high risk for compli-
cations and documents the safety of the restrictive deferred 
hydration combined with preemptive norepinephrine infu-
sion. The complication rate in the control group is in line 
Table 3. (Continued)
Characteristic
Low-volume Group
(n = 83)
Control Group
(n = 83) P Value
Hospital discharge
  Weight difference vs. preoperative (kg/BW) −1.8 [−10 to +4] −1.0 [−12 to +4] 0.62
  Hemoglobin (g/dl) 9.5 [7.4–13.2] 9.8 [7.2–13.2] 0.31
  Hematocrit 0.29 [0.22–0.42] 0.30 [0.20–0.39] 0.19
  Serum creatinine (µM) 76 [28–222] 72 [40–197] 0.23
  eGFR (MDRD)/1.73 m2 (ml/min) 80 [23–90] 88 [22–90] 0.58
  Brain natriuretic peptide (pg/ml) 50 [10–341] 54 [17–379] 0.99
Data are presented as median [ranges] or absolute value (%).
BW = body weight; eGFR = estimated glomerular filtration rate; MDRD = modification of diet in renal disease; POD = postoperative day; ScvO2 = central 
venous oxygen saturation.
Table 4. In-hospital Complications
Category Complication
Low-volume  
Group
(n = 83)
Control  
Group
(n = 83) RR 95% CI P Value
Gastrointestinal 5 (6%) 31 (37%) 0.16 0.07–0.39 <0.001
Ileus 0 (0%) 8 (10%) 0.001
Constipation 2 (2%) 18 (22%) <0.001
Gastrointestinal bleeding 1 (1%) 2 (2%) 0.99
Gastric ulcer 2 (2%) 2 (2%) 1
Anastomotic bowel leak 0 (0%) 1 (1%) 0.32
Infectious 16 (19%) 20 (24%) 0.80 0.45–1.43 0.57
Urinary tract infection 7 (8%) 7 (8%) 1
Pyelonephritis 4 (5%) 3 (4%) 1
Urosepsis 0 (0%) 1 (1%) 1
Pneumonia 2 (2%) 4 (5%) 0.41
Wound infection 3 (4%) 5 (6%) 0.72
Wound Wound dehiscence 3 (4%) 4 (5%) 0.75 0.17–3.24 1
Genitourinary 7 (8%) 14 (17%) 0.50 0.21–1.17 0.16
Renal failure 4 (5%) 3 (4%) 0.08
Transient increase of creatinine 2 (2%) 5 (6%) 0.32
Urethral anastomosis leakage 1 (1%) 6 (7%) 0.10
Cardiac 17 (20%) 40 (48%) 0.43 0.26–0.69 <0.001
Acute myocardial infarction (all NSTEMI) 1 (1%) 6 (7%) 0.10
Arrhythmia 3 (4%) 3 (4%) 1
Congestive heart failure 2 (2%) 3 (4%) 0.65
Transient BNP increase 11 (13%) 28 (34%) <0.001
Thromboembolic Pulmonary embolism 1 (1%) 4 (5%) 0.25 0.03–2.20 0.17
Blood loss Anemia requiring postoperative transfusion 23 (28%) 40 (48%) 0.58 0.38–0.87 0.01
Neurological 2 (2%) 6 (7%) 0.33 0.07–1.61 0.28
Peripheral neuropathy 1 (1%) 2 (2%) 1
Delirium/agitation 1 (1%) 4 (5%) 0.37
Miscellaneous 3 (4%) 2 (2%) 1.50 0.26–8.75 1
Lymphocele 3 (4%) 1 (1%) 0.62
Vascular injury 0 (0%) 1 (1%) 1
Total number of complications 77 161
Total number of patients with complications 43 (52%) 61 (73%) 0.70 0.55–0.88 0.006
Number of patients with more than one complication 26 (31%) 37 (45%) 0.70 0.47–1.05 0.11
BNP = brain natriuretic peptide; NSTEMI = non-ST elevation myocardial infarction; RR = relative risk.
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with the complication rates reported by other high case-load 
institutions, despite the fact that in this study complications 
were graded according to the modified Clavien–Dindo clas-
sification.10,32 This is of importance because it indicates that 
the complication rate in the control group, although signifi-
cantly higher than in the low-volume group, was not exces-
sive when compared with rates in other centers of excellence.
Although serum creatinine values were increased in the 
low-volume group on POD 1 (most likely because of less 
serum dilution), renal function (serum creatinine values, 
estimated glomerular filtration rate, and urine osmolality) 
did not differ between the groups from POD 2 until dis-
charge. Fluid restriction and the adjuvant use of norepi-
nephrine did not result in more renal complications and a 
more liberal fluid administration did not appear to have a 
protective effect on renal function. On the basis of these 
findings, the often assumed beneficial effect of preopera-
tive fluid boluses and liberal fluid administration to pro-
tect renal function seems questionable.33 It has been shown 
that intraoperative urinary output is dependent not only 
on fluid management but also on the intraoperative release 
of stress hormones, osmolality, and adiuretin secretion.34
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Fig. 2. In-hospital complications that patients experienced, 
by highest grade according to the Clavien–Dindo classifica-
tion (minor complications: grade I to II; major complications: 
grade IIIa to V).
Table 5. Multiple Regression Analysis Evaluating Relevant Predictors Associated with In-hospital Complications  
(P < 0.10 Considered as Significant)
Predictors OR 95% CI P Value
Group (low-volume vs. control) 0.439 0.210–0.920 0.029
BMI (per increasing value) 1.127 1.012–1.254 0.030
BNP (per increasing value) 1.013 1.000–1.026 0.045
Preoperative anemia (no vs. yes) 0.426 0.177–1.022 0.056
GPS (per increasing value) 1.606 0.929–2.777 0.089
Age (<65 yr vs. ≥85 yr) 0.860 0.067–11.055 0.993
Age (65–74 yr vs. ≥85 yr) 0.536 0.059–4.830 0.216
Age (75–84 yr vs. ≥85 yr) 1.164 0.144–9.428 0.513
Neoadjuvant chemotherapy (no vs. yes) 0.951 0.318–2.845 0.929
ASA physical status score (II vs. III) 0.998 0.390–2.550 0.996
CCI age adjusted (per increasing value) 1.210 0.772–1.895 0.405
Urinary diversion (ileal conduit vs. ileal orthotopic bladder substitution) 0.643 0.239–1.732 0.383
ASA = American Society of Anesthesiologists; BMI = body mass index; BNP = brain natriuretic peptide; CCI = Charlson Comorbidity Index; GPS = Glasgow 
Prognostic Score; OR = odds ratio.
Table 6. 90-day Postoperative Complications Experienced by Highest Grade by Patients According to the Clavien–Dindo 
Classification System
Complication
Low-volume Group
(n = 83)
Control Group
(n = 83) RR 95% CI P Value
Grade I 10 (12%) 9 (11%)
Grade II 23 (28%) 33 (39%)
Grade IIIa 5 (6%) 7 (8%)
Grade IIIb 5 (6%) 5 (6%)
Grade IVa 1 (1%) 5 (6%)
Grade V 0 (0%) 4 (5%)
Total 44 (53%) 63 (75%) 0.67 0.54–0.87 0.0019
RR = relative risk.
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Major concern is often voiced concerning the vasocon-
strictive effect of norepinephrine. Our results document, 
however, that the preemptive norepinephrine infusion at 
an initial rate of 2 µg·kg−1·h−1 has no identifiable nega-
tive consequences. On the contrary, it counteracts the 
decreased sympathetic tone and vasodilatation induced by 
epidural analgesia, anesthetics, and analgesics and may be 
more physiological at compensating for a plegic vascular 
system than the liberal use of IV fluids. This is also sub-
stantiated by the overall lower complication rate in this 
group. In addition, although postoperative serum BNP 
and transient creatinine level increases were rated by us 
as complications, which makes difficult the comparison 
with other series that did not include these parameters, the 
incidence of overall complications, using similar Clavien–
Dindo classification, in the low-volume group was still 
lower than that of other major urological centers.10,32 Our 
results call into question the current policy of liberal fluid 
administration to replace basic fluid volume depleted by, 
e.g., perspiration, exudation through the surgical wound, 
loss into the third space, and to correct hypotension due 
to vasodilation.1,3,6,35
Besides the preemptive and concomitant use of norepi-
nephrine, our low-volume group protocol differed from 
protocols of precedent studies because of the deferred 
fluid administration: less fluid was administrated during 
pelvic lymph node dissection and cystectomy (the main 
period of bleeding); thereafter during construction of the 
urinary diversion more fluid was administered. This may 
explain why blood loss was significantly reduced in the 
low-volume group and consequently, less packed eryth-
rocytes units was transfused perioperatively. This again 
could explain the enhanced recovery in the low-volume 
group.36
A possible limitation of this study is that the low-volume 
group is not compared with a GDT protocol, a mode of fluid 
management that has been shown to enhance bowel recovery 
and shorten hospitalization time after abdominal surgery.25 
The GDT approach, which consists of a baseline fluid sub-
stitution with additional fluid boli to optimize cardiac pre-
load, is generally associated with more fluid administration 
(including colloids), than administered in our control group. 
In addition, the routine or preemptive use of norepinephrine 
administration was not a first-line option in GDT protocols 
in contrast to our protocol.2,25,37,38 In a previous randomized 
trial comparing the effect of GDT (14 ml·kg−1·h−1) with that 
of standard intraoperative fluids administered at the discre-
tion of the anesthesiologist (11 ml·kg−1·h−1) on bowel func-
tion after radical cystectomy, a significant reduction of ileus 
was noted in the GDT group (22 vs. 53%).38 By compari-
son, the rates of constipation and ileus in both our groups 
were far lower. This could be explained not only because of 
the intraoperative hydration, but also by the fact that in the 
study by Pillai et al.,38 not every patient had an epidural anal-
gesia and it was instituted only for 48 h. In addition, our 
finding is in line with a recent study showing that GDT and 
a zero fluid balance fluid regimen have similar complication 
rates after colorectal surgery.6 Our results using intraopera-
tive restrictive deferred hydration combined with preemp-
tive norepinephrine infusion raise questions concerning the 
validity of GDT or liberal intraoperative fluid administra-
tion (as in Pillai et al.’s control group) during open radical 
cystectomy and urinary diversion.
A minor limitation of this study is the lack of continuous 
ScvO2 monitoring. We only measured ScvO2 at three time-points 
during surgery and thus, cannot exclude that ScvO2 values less 
than 70% occurred intraoperatively in both groups.
A strength of this study is that because all patients were 
managed with the same postoperative enhanced recovery 
protocol, the risk of possible confounding factors caused by 
individualized postoperative management is limited. And 
because no patients were lost to postoperative follow-up, it is 
unlikely that any complications were missed.
In conclusion, restrictive deferred fluid management 
combined with preemptive norepinephrine administration 
in patients undergoing standardized pelvic lymph node 
dissection, open radical cystectomy, and urinary diversion 
resulting in a postoperative zero fluid balance, lower in-
hospital and 90-day postoperative complication rates, and 
reduced hospitalization time.
Appendix. Definitions of Postoperative 
Complications/Events
Gastrointestinal Complications
Ileus: no evidence of bowel function (no flatus and no passage of 
stool) with abdominal distension requiring cessation of oral intake 
and intravenous fluid support by POD 510
Constipation: no passage of stool without signs of ileus by 
POD 510
Gastric ulcer: diagnosis made by gastroscopy
Anastomotic bowel leak: considered as a complication if requir-
ing surgery or prolonged drainage
Complications of Infections
Urinary tract infection: temperature >38°C in the last 24 h and leu-
kocytosis and a prompted urinary analysis that showed bacterial 
counts >100,000 requiring antibiotics
Sepsis: bacterial infection and at least two of the following clini-
cal signs: hypo- or hyperthermia, tachycardia, tachypnea, leukocy-
topenia or leukocytosis, positive blood culture3
Pneumonia: temperature >38°C and leukocytosis and clinical 
signs of pneumonia, requiring antibiotics
Wound infection: pus can be expressed or aspirated, requiring 
surgical intervention
Wound Complications
Wound dehiscence: diagnosed clinically and requiring resuturing
Cardiac Events
Myocardial infarction: increase of the enzyme high-sensitive tropo-
nin T above the hospital laboratory’s myocardial infarction thresh-
old (>0.05 µg/l), and either new Q wave changes, or persistent 
changes in ST-T segments
Anesthesiology 2014; 120:365-77 376 Wuethrich et al.
Intraoperative Hydration and Postoperative Complications
Arrhythmia: confirmed by 12-lead electrocardiography and 
requiring new medication or electroconversion
Congestive heart failure and pulmonary edema: shortness of 
breath, rales, jugular venous distension, peripheral edema, third 
heart sound, radiologic signs (cardiomegaly, interstitial or alveolar 
edema), brain natriuretic peptide value >500 pg/ml and diagnosis 
requiring diuretics
Transient brain natriuretic peptide increase: postoperative serum 
brain natriuretic peptide values between 100 and 500 pg/ml (con-
sidered as minor cardiac event)
Thromboembolic Complications
Pulmonary embolism: evidenced by spiral computerized tomogra-
phy scanning3
Genitourinary Complications
Renal dysfunction: transient increase of creatinine: creatinine 
>50% upper limit of normal value3
Renal failure: severe reduction in glomerular filtration rate (15–
29 ml·min−1·1.73 m−2) at discharge
Urinary leakage: radiologically diagnosed, requiring stenting
Neurological Complications
Presence of a de novo focal deficit, confusion/delirium
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